View Older Stories View More Recent Stories

Mar 25, 2025 08:00AM Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Mar 17, 2025 08:00AM Mineralys Therapeutics (MLYS) Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat
Mar 17, 2025 08:00AM Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College
Mar 10, 2025 07:01AM Mineralys Therapeutics (MLYS) Announces Positive Topline Results from Launch-HTN and Advance-HTN Trials of Lorundrostat
Mar 10, 2025 07:00AM Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
Mar 7, 2025 04:01PM Mineralys Therapeutics (MLYS) to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Mar 7, 2025 04:01PM Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Feb 12, 2025 07:00AM Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Feb 5, 2025 04:05PM Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
Feb 4, 2025 08:06AM Mineralys Therapeutics (MLYS) Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Feb 4, 2025 08:00AM Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Jan 8, 2025 08:06AM Mineralys Therapeutics (MLYS) Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Jan 8, 2025 08:00AM Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Nov 11, 2024 04:05PM Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 5, 2024 04:05PM Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Nov 4, 2024 04:05PM Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
Oct 30, 2024 08:00AM Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Oct 22, 2024 08:00AM Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
Sep 25, 2024 08:00AM Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
Aug 28, 2024 08:00AM Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
Aug 13, 2024 04:05PM Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 5, 2024 04:05PM Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Jun 14, 2024 08:01AM Mineralys Therapeutics (MLYS) Appoints Alexander M. Gold to its Board
Jun 14, 2024 08:00AM Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
Jun 3, 2024 08:00AM Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 9, 2024 07:00AM Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6, 2024 08:00AM Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 2, 2024 08:00AM Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
Mar 21, 2024 07:00AM Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Jan 29, 2024 04:05PM Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
Jan 4, 2024 04:05PM Mineralys Therapeutics (MLYS) Appoints Minji Kim as Chief Business Officer
Jan 4, 2024 04:05PM Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
Dec 21, 2023 04:05PM Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Nov 11, 2023 11:30AM Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
Nov 9, 2023 04:05PM Mineralys Therapeutics to Participate in Three Upcoming Conferences
Nov 7, 2023 04:05PM Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 2, 2023 10:00AM Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
Oct 31, 2023 04:05PM Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
Oct 13, 2023 04:10PM Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
Sep 14, 2023 04:06PM Mineralys Therapeutics (MLYS) Appoints Glenn Sblendorio and Daphne Karydas to its Board
Sep 14, 2023 04:05PM Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas
Sep 11, 2023 04:05PM Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023
Sep 11, 2023 05:43AM Mineralys Therapeutics (MLYS) Presents Target-HTN Phase 2 Trial Results
Sep 11, 2023 05:42AM Mineralys Therapeutics (MLYS) Reports Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat
Sep 10, 2023 07:47AM Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
Sep 10, 2023 07:45AM Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions
Sep 5, 2023 04:05PM Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions
Aug 29, 2023 04:05PM Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023
Aug 7, 2023 04:05PM Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 17, 2023 04:01PM Mineralys Therapeutics (MLYS) Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with CKD
View More Recent Stories View Older Stories